Rubedo's Anti-Aging Drug Shows Early Promise in Human Trials

SAN FRANCISCO, CA – March 26, 2026 – Biotech firm Rubedo Life Sciences has unveiled promising preliminary results from the first human trial of its lead drug candidate, RLS-1496. The Phase 1 study showed the topical treatment was safe and demonstrated early signs of clinical efficacy in patients with plaque psoriasis, atopic dermatitis, and sun-damaged skin. The announcement marks a significant milestone, as RLS-1496 is the first-ever therapy designed to selectively modulate an enzyme called GPX4 to enter human trials, representing a novel approach aimed at cellular rejuvenation.

A New Frontier in Cellular Rejuvenation

At the heart of Rubedo's strategy is a focus on cellular senescence, a process where aging or damaged cells stop dividing but remain in the body. These so-called “zombie cells” accumulate over time, releasing a cocktail of inflammatory proteins that contribute to chronic inflammation, tissue degradation, and a host of age-related diseases. For years, scientists have theorized that selectively removing these cells—a process known as senolysis—could halt or even reverse disease progression.

RLS-1496 represents a highly targeted approach to this problem. It is a first-in-class modulator of glutathione peroxidase 4 (GPX4), an enzyme critical for protecting cells from a specific type of programmed cell death called ferroptosis. Pathologic senescent cells are believed to have an imbalance in GPX4, making them uniquely vulnerable. By modulating this enzyme, RLS-1496 is designed to trigger ferroptosis exclusively in these harmful aged cells, clearing them out while leaving healthy cells unharmed. This mechanism not only removes the source of chronic inflammation but also helps restore healthy tissue function.

“This is one of the first comprehensively evaluated trials of a senotherapeutic drug that targets aging pathologic cells and regenerates healthy cells, and also the first human trial of a GPX4 modulator,” said Rubedo Chief Scientific Officer and Founder Marco Quarta, PhD. “These preliminary results show the drug working mechanistically as expected and even better than should be expected clinically in a 4-week trial.”

Promising Early Results Across Multiple Conditions

The recently completed Phase 1 trial, a randomized, double-blind, vehicle-controlled study conducted in the European Union, met its primary goal of demonstrating safety and tolerability. Over the four-week treatment period, no serious adverse events were reported, and no participants discontinued the study due to side effects. Beyond safety, the trial yielded compelling early evidence of the drug's intended biological activity and clinical benefits, a rare feat for a short-duration Phase 1 dermatology study.

For patients with plaque psoriasis, the study observed a clear dose-dependent response, with the highest concentration (1.0%) proving well-tolerated and selected for future evaluation. Researchers confirmed that the drug was engaging its GPX4 target and observed a corresponding reduction in senescent cells in the treated skin. This cellular change was associated with a decrease in key inflammatory biomarkers, such as IL-19 and S100A7, which are known drivers of psoriasis. Histological analysis revealed an average 20% reduction in epidermal thickness—a key indicator of disease—in subjects treated with RLS-1496 for just one month.

In patients with atopic dermatitis, or eczema, the results were also encouraging. The press release noted substantial clinical improvement and high levels of target engagement. Significantly, 25% of subjects treated with RLS-1496 reported a four-point or greater reduction in pruritus (itching) on a standard numeric rating scale. No subjects in the placebo group achieved this level of relief, pointing to a meaningful improvement in quality of life for a condition defined by intense discomfort.

Early data on photo-aged skin also suggest a rejuvenating effect. Analysis showed that RLS-1496 treatments led to an increase in collagen gene and protein expression in dermal fibroblasts, the cells responsible for skin structure and elasticity. Furthermore, spatial transcriptomics—an advanced imaging technique—indicated a decrease in inflammatory signals in keratinocytes, the primary cells of the skin's outer layer.

“We’re pleased by the positive safety and tolerability seen in the trial, with the additional preliminary results exceeding our expectations by showing very promising and clinically meaningful results,” said Rubedo CEO Frederick Beddingfield, III, MD, PhD. “It’s uncommon to see clinical effect in a Phase 1 dermatology study given the shorter study duration and smaller sample size, and we are excited by the potential of this treatment.”

The Power of AI in Accelerating Drug Discovery

The rapid and targeted development of RLS-1496 was powered by Rubedo's proprietary artificial intelligence platform, ALEMBIC™. This system integrates computational biology with chemistry to dramatically accelerate the drug discovery process. By analyzing vast datasets from single-cell sequencing, ALEMBIC™ can pinpoint novel druggable targets that are unique to pathologic senescent cells in specific diseases.

This high-resolution approach allows the company to design small molecules that are highly selective, increasing their efficacy while minimizing potential side effects on healthy tissue. The company claims this AI-driven method enabled it to advance RLS-1496 from concept to clinical candidate in under three years—roughly twice as fast as the industry average. This combination of AI-powered target identification and precision chemistry represents a significant leap forward in creating a new class of cellular rejuvenation medicines.

Strategic Backing and Future Pathways

Rubedo's innovative approach has attracted significant financial and strategic support. In April 2024, the company secured $40 million in a Series A financing round co-led by Khosla Ventures and Ahren Innovation Capital, with participation from a syndicate of longevity-focused funds and corporate venture arms, including that of German skincare giant Beiersdorf AG.

The partnership with Beiersdorf aims to leverage Rubedo’s technology to develop novel anti-aging skincare products, highlighting the broad commercial potential of its platform. This collaboration, along with another strategic partnership with Saudi Arabia's SVAX, underscores growing confidence in the company's senolytic pipeline.

With these positive initial results in hand, Rubedo is already advancing its clinical program. A second U.S.-based study, a Phase 1b/2a trial for RLS-1496 in treating actinic keratosis (a common precancerous skin lesion), is underway and expected to complete later this year. This trial, along with the first, will contribute to a large dataset on the effects of RLS-1496 on aging skin from approximately 70 subjects. Dr. Beddingfield is scheduled to preview these results at the Dermatology Innovation Forum in Denver, with a more comprehensive data presentation planned for the Society for Investigative Dermatology (SID) annual meeting in May 2026.